| Analysis | Metabolite Name | Measured Value | Units | Group | TIMEPOINT |
|---|---|---|---|---|---|
| Reversed phase NEGATIVE ION MODE | glycolithocholate | 0.3213 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | glycolithocholate | 0.3213 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycolithocholate | 0.3213 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycolithocholate | 0.3213 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycolithocholate | 0.3213 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycolithocholate | 0.3213 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | glycolithocholate | 0.3213 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | glycolithocholate | 0.3213 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycolithocholate | 0.3213 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycolithocholate | 0.3213 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycolithocholate | 0.3213 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycolithocholate | 0.3213 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | glycolithocholate | 0.3213 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | glycolithocholate | 0.3213 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycolithocholate | 0.3213 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycolithocholate | 0.3213 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycolithocholate | 0.3213 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycolithocholate | 0.3213 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | glycolithocholate | 0.3767 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | glycolithocholate | 0.3775 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycolithocholate | 0.4079 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | glycolithocholate | 0.4104 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycolithocholate | 0.4380 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | glycolithocholate | 0.4720 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | glycolithocholate | 0.5132 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | glycolithocholate | 0.5217 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | glycolithocholate | 0.5683 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycolithocholate | 0.5724 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycolithocholate | 0.5975 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycolithocholate | 0.6099 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycolithocholate | 0.6450 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | glycolithocholate | 0.6537 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycolithocholate | 0.6954 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycolithocholate | 0.6989 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | glycolithocholate | 0.7223 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | glycolithocholate | 0.7279 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycolithocholate | 0.7284 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycolithocholate | 0.7360 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | glycolithocholate | 0.7575 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycolithocholate | 0.7693 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | glycolithocholate | 0.7923 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycolithocholate | 0.7928 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycolithocholate | 0.7940 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycolithocholate | 0.8044 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycolithocholate | 0.8565 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | glycolithocholate | 0.8765 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycolithocholate | 0.8811 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | glycolithocholate | 0.8943 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycolithocholate | 0.9085 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycolithocholate | 0.9085 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | glycolithocholate | 0.9105 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | glycolithocholate | 0.9310 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | glycolithocholate | 0.9669 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycolithocholate | 0.9812 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | glycolithocholate | 0.9826 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycolithocholate | 1.0174 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | glycolithocholate | 1.0188 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycolithocholate | 1.1007 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | glycolithocholate | 1.2100 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycolithocholate | 1.2105 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycolithocholate | 1.2201 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | glycolithocholate | 1.2215 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | glycolithocholate | 1.2459 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycolithocholate | 1.2482 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycolithocholate | 1.2573 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | glycolithocholate | 1.2619 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | glycolithocholate | 1.2620 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycolithocholate | 1.2642 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycolithocholate | 1.4262 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycolithocholate | 1.4972 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | glycolithocholate | 1.5468 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycolithocholate | 1.5647 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | glycolithocholate | 1.5869 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | glycolithocholate | 1.5907 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycolithocholate | 1.6045 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | glycolithocholate | 1.6409 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycolithocholate | 1.6445 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | glycolithocholate | 1.6962 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycolithocholate | 1.7660 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycolithocholate | 1.9977 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycolithocholate | 2.0790 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycolithocholate | 2.2264 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycolithocholate | 2.8667 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | glycolithocholate | 3.0177 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | glycolithocholate | 3.0717 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycolithocholate | 3.0748 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | glycolithocholate | 3.3499 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycolithocholate | 3.4746 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | glycolithocholate | 3.4929 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycolithocholate | 3.6452 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycolithocholate | 4.4314 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycolithocholate | 6.3269 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | glycolithocholate | 8.7317 | scaled units | High-Dose | -0.5HR |
- UCSD Metabolomics Workbench, a resource sponsored by the Common Fund of the National Institutes of Health
|